ITPA and anemia: The findings from the NORDynamIC study, enrolling 382 HCV genotype 2- or 3-infected patients treated with standard 800-mg dosing of ribavirin in combination with interferon, demonstrated that patients carrying ITPA variants encoding reduced ITPase activity showed increased treatment efficacy mediated by reduced relapse risk and less anemia (2).